SBIR/STTR Research Award

Development of a MMP Inhibitor for Neuropathic Pain

Award identifier 278c4951f211bc407e6949621cc60d60eb5c4191cccde43655aa118db75fb163Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,931,422

Program and phase

SBIR · Phase II

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AQUILUS PHARMACEUTICALS INC
Proposal award date
2015-08-01
Contract end date
2019-07-31
UEI
EM9ULMXK5F21
Solicitation number
PA14-071
Topic code
NIDCR

Research abstract

DESCRIPTION provided by applicant Aquilus Pharmaceuticals Inc proposes to preclinically develop AQU for the treatment of orofacial and general neuropathic pain via a newly discovered mechanism involving matrix metalloproteinases andamp MMP MMP AQU is a non hydroxamic acid containing MMP inhibitor that is selective for both MMP and MMP and has been shown to block mechanical allodynia in both the spinal nerve ligation SNL and the chronic constriction injury of the infraorbital nerve CCI IoN rodent models of neuropathic pain The goals for Phase II are to scale up the synthesis of AQU determine its phamacokinetics andamp phamacodynamics PK PD in the SNL rat model and complete in vitro safety studies within the first year Year two will entail the process research andamp development PRD of the synthetic scale up of AQU culminating in its GMP manufacture as well completing various pivotol GLP animal toxicity studies The ultimate goal of the proposed work is to rapidly develop a safe and effective drug for the treatment of chronic orofacial and general neuropathic pain that produces no addictive or euphoric side effects PUBLIC HEALTH RELEVANCE Millions of Americans suffer from chronic neuropathic pain for which no current single drug treatment is effective in more than of patients Of those drugs that are effective their side effect profile and or propensity for addiction make them poor candidates for long term use Aquilus Pharmaceuticals plans to develop a compound that has been found to block neuropathic pain in various animal models via a newly discovered pain pathway The purpose of the proposed work is to further study this new compound and determine whether it is safe enough and can be made in sufficient quantities to be tested in humans If the project is successful Aquilus Pharmaceuticals will be able to bring to the clinic a pain drug with a novel mechanism of action that would be focused on the treatment of chronic orofacial and general neuropathic pain without producing any addictive or euphoric side effects

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (2011–2019). Reported award amounts total $3,562,237. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.